Lactoferrin-monophosphoryl lipid a complex enhances immunity of mice to Plesiomonas shigelloides CNCTC 138/92

• Authors: Grzegorz Chodaczek , Michal Zimecki , Jolanta Lukasiewicz , Czesław Lugowski
• Languages of publication: EN

Abstracts

EN

Our previous study showed the efficacy of lactoferrin-monophosphoryl lipid A isolated from Hafnia alvei LPS complex (LF-MPLH.a.) as an adjuvant in stimulation of humoral and cellular immune response in mice to conventional antigens and a lower pyrogenicity of the complex as compared with MPLH.a. alone. In the present investigation we demonstrated that LF-MPLH.a. complex enhanced the immunity of BALB/c mice immunized with Plesiomonas shigelloides CNCTC 138/92 bacterial vaccine, against P. shigelloides infection. The adjuvant effect was evidenced by a significant increase of the antigen-specific serum IgG, IgG2a, and IgG1 and elevation of antigen-specific serum IgA concentrations. In addition, application of the adjuvant facilitated better clearance of the bacteria in spleens and livers of infected mice when compared with MPLH.a. alone. These features of the new adjuvant may predispose it for vaccination protocols in humans.

Keywords

EN

lactoferrin; Plesiomonas shigelloides; adjuvant; monophosphoryl lipid A

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2008
• Volume: 55
• Issue: 1
• Pages: 91-96

Dates

published

2008

received

2007-06-01

revised

2007-11-27

accepted

2007-11-30

(unknown)

2008-01-30

Contributors

author

Grzegorz Chodaczek

• Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

author

Michal Zimecki

• Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

author

Jolanta Lukasiewicz

• Department of Immunochemistry, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

author

Czesław Lugowski

• Department of Cell Biology, University of Opole, Opole, Poland

References

• Actor JK, Hwang SA, Olsen M, Zimecki M, Hunter RL Jr, Kruzel ML (2002) Lactoferrin immunomodulation of DTH response in mice. Int Immunopharmacol 2: 475-486.
• Appelmelk BJ, An YQ, Geerts M, Thijs BG, de Boer HA, MacLaren DM et al. (1994) Lactoferrin is a lipid A-binding protein. Infect Immun 62: 2628-2632.
• Chodaczek G, Zimecki M, Lukasiewicz J, Lugowski C (2006) A complex of lactoferrin with monophosphoryl lipid A is an efficient adjuvant of the humoral and cellular immune response in mice. Med Microbiol Immunol (Berl). 195: 207-216
• Cox JC, Coulter AR (1997) Adjuvants - a classification and review of their modes of action. Vaccine 15: 248-256.
• Debbabi H, Dubarry M, Rautureau M, Tome D (1998) Bovine lactoferrin induces both mucosal and systemic immune response in mice. J Dairy Res 65: 283-293.
• Gregory SH, Wing EJ (2002) Neutrophil-Kupffer cell interaction: a critical component of host defenses to systemic bacterial infections. J Leukoc Biol 72: 239-248.
• Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK (1993) Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 11: 293-306.
• Jennings HJ, Lugowski C (1981) Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 127: 1011-1018.
• Legrand D, Elass E, Carpentier M, Mazurier J (2005) Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci 62: 2549-2559.
• Lukasiewicz J, Jachymek W, Niedziela T, Malik-Gebicka M, Dzieciatkowska M, Lugowski C (2002) Comparison of serological specificity of anti-endotoxin sera directed against whole bacterial cells and core oligosaccharide of Escherichia coli J5-tetanus toxoid conjugate. Acta Biochim Polon 49: 721-734.
• Lukasiewicz J, Jachymek W, Niedziela T, Dzieciatkowska M, Lakomska J, Miedzybrodzki R et al. (2003) Serological characterization of anti-endotoxin serum directed against the conjugate of oligosaccharide core of Escherichia coli type R4 with tetanus toxoid. FEMS Immunol Med Microbiol 37: 59-67.
• Martin M, Michalek SM, Katz J (2003) Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 71: 2498-2507.
• McCluskie MJ, Weeratna RD (2001) Novel adjuvant systems. Curr Drug Targets Infect Disord 1: 263-271.
• Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM et al. (2002) Taking toll : lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 10: S32-37.
• Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR et al. (1988) Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334: 255-258.
• Stock, I. (2004) Plesiomonas shigelloides: an emerging pathogen with unusual properties. Rev Med Microbiol 15: 129-139.
• Suzuki YA, Lopez V, Lonnerdal B (2005) Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci 62: 2560-2575.
• Westphal O, Jann K (1965) Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr Chem 5: 83-89.
• Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z (1989) Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br J Exp Pathol 70: 697-704.
• Zimecki M, Kruzel ML (2000) Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice. Immunol Lett 74: 183-188.
• Zimecki M, Mazurier J, Spik G, Kapp JA (1996) Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines. Arch Immunol Ther Exp (Warsz) 44: 51-56.
• Zimecki M, Kocieba M, Kruzel M (2002) Immunoregulatory activities of lactoferrin in the delayed type hypersensitivity in mice are mediated by a receptor with affinity to mannose. Immunobiology 205: 120-131.
• Zimecki M, Artym J, Chodaczek G, Kocieba M, Kruzel ML (2004) Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflamm Res 53: 292-296.